Advances in the treatment of cutaneous tumors: from conventional therapies to targeted and immunotherapeutic strategies.

Nonetheless, the T-VEC-pembrolizumab group showed a numerical trend toward longer median PFS (14.3 months vs. 8.5 months) and slightly higher ORR (48.6% vs. 41.3%) and DRR(42.2% vs. 34.1%), while maintaining a comparable safety profile [ 74 ].Although the combination of T-VEC and pembrolizumab did not achieve a significant overall survival advantage in the first-line setting for advanced melanoma, it remains under active investigation in PD-1 inhibitor-refractory melanoma and other malignancies.

also in 723 other papers